BioDuro Opens State-of-the-Art Discovery Lab in Shanghai

 

New facility offers customized portfolio of services to meet expanding client demand
 
WILMINGTON, N.C. – BioDuro, A PPD® Company, today announced it has opened a new state-of-the-art laboratory in Shanghai, strengthening its ability to provide biopharmaceutical clients an extensive range of customized drug discovery services in Asia Pacific. The new lab also enables the company to better support the business needs of its clients by increasing efficiency during discovery and development, and providing greater consistency among the stages of development. In addition, the location of the lab in the Waigaoqiao Free Trade Zone and its proximity to local and multinational pharmaceutical and biotechnology companies in Shanghai will foster their working relationship with BioDuro.
 
The 72,000-square-foot lab, accompanied by 20,000 square feet of office space, offers integrated drug metabolism and pharmacokinetic (DMPK), bioanalytical, chemistry, discovery biology and oncology pharmacology services. And, because BioDuro is part of the PPD organization, clients also are able to take advantage of a complete menu of clinical research services, as well as an extensive library of assays for testing.
 
"As a fully integrated life science research service provider, BioDuro has an experienced team of researchers and scientists with expertise in a wide range of drug discovery services," said Jasmine Cui, Ph.D., general manager and chief scientific officer of BioDuro. "This new lab will allow us to meet the business needs of our clients more effectively by streamlining the discovery and development process, and continuing to enhance continuity and smooth transitions throughout the stages of development. For example, after a compound goes into Phase 0, the PPD organization can offer full clinical research services to develop the compound through post approval."
 
BioDuro also has a state-of-the-art, 110,000-square-foot laboratory in Beijing. Through the two operations, BioDuro provides fully integrated, comprehensive drug discovery services covering development from target identification to preclinical/Phase 0.
 
Contacts
Media:
Randy Buckwalter
+1 919 456 4425
 
Investors:
Luke Heagle
+1 910 558 7585
 
About BioDuro
BioDuro, acquired by PPD in 2009, is a leading drug discovery services company. It provides high-quality, integrated preclinical research and development services to biopharmaceutical clients, ranging from medicinal chemistry, discovery biology, pharmacology, DMPK and biologics. For more information, visit www.bioduro.com.
 
About PPD
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.